Certara, a provider of drug discovery and development software and scientific consulting services, will acquire U.K-based Simcyp, a research company providing a modeling and simulation platform for predicting the fate of drugs in virtual populations.

Simcyp will join the Certara portfolio and provide key, extensible technologies that support Certara’s translational science initiatives.

“The capabilities offered by Simcyp’s preclinical technologies, combined with our existing software products and scientific consulting services, will provide significant drug development advantages to our mutual and prospective clients,” said Jim Hopkins, CEO and president of Cerara. “This means broader capabilities to predict drug disposition as a function of molecular structure, and the ability to utilize a single unified suite of tools to facilitate preclinical and clinical PBPK and PKPD modeling and analysis.”

Clients from across the spectrum of drug discovery and development will have access to an expanded and integrated range of products and services, through the combination of Tripos, Simcyp and Pharsight science and functionality, according to Hopkins.